Paragraph 6

Intervention of Brazil to the WTO TRIPS Council (March 2011) providing details about the Brazilian HIV treatment program

On Tuesday, 1 March 2011, Brazil made the following intervention at the WTO Council for TRIPS during discussions of the paragraph 6 system.

Mr. Chairman,
 
Brazil welcomes the opportunity for this follow-up to the review on the implementation of the paragraph 6 system. Our aim here is to assess whether this system is indeed an expeditious solution for countries lacking manufacturing capacity and to address any shortcomings for the system’s effective operation.
 

Statement of the United States to WTO TRIPS Council on the Paragraph 6 System

The following statement was delivered by USTR at the WTO Council for TRIPS Annual Review of the Paragraph 6 System on Wednesday, 27 October 2010.

Statement of the United States
Agenda item F, Annual Review of the Paragraph 6 System
Topic 5

Mr. Chairman

We are pleased to be here today to participate in the annual review on the implementation of paragraph 6 of the Doha Declaration.

Canada's Intervention to TRIPS Council: Experience using the System (Apotex-Rwanda Case)

On Wednesday, 27 October 2010, Canada delivered the three interventions to the WTO TRIPS Council related to the review of the Paragraph 6 system. The first intervention below details the Canadian experience using the Paragraph 6 system in the case of Apotex and Rwanda.

CANADA Intervention: (1) Experience using the System (Apotex-Rwanda Case)

As we recall, the 2003 WTO Decision on TRIPS and Public Health was an intensely negotiated decision that garnered unanimous support from all WTO Members.

Rethinking compulsory licensing for export: WTO members hold informal consultations on Paragraph 6 implementation

Friday, 12 February 2010

Around 100 Members of the World Trade Organization attended informal consultations today in Room E (a mainstay of the green room consultations) to discuss the implementation of Paragraph 6 mechanism which was created to be an "an expeditious solution" for "WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector" that faced difficulties in in "making effective use of compulsory licensing under the TRIPS Agreement".

Syndicate content